Cidara Therapeutics (CDTX) filed a registration statement Monday with the US Securities and Exchange Commission covering the potential resale of up to 7.04 million common shares by certain stockholders from time to time.
The company said that 3.89 million of the shares are issued and outstanding, while the remaining are issuable upon the exercise of prefunded warrants.
Cidara isn't selling any shares under the statement and won't receive any proceeds from the sale by the investors.
The company's shares fell 1.7% in after-hours activity.
Price: 23.01, Change: -0.39, Percent Change: -1.67
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments